Creative Planning Immuno Gen, Inc. Transaction History

Creative Planning

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $121,958 - $293,150	9,788 Added 48.94%	29,788 $883,000
Q3 2023 Nov 16, 2023	BUY	$14.09 - $19.87 $44,820 - $63,206	3,181 Added 18.91%	20,000 $317,000
Q2 2023 Jul 21, 2023	BUY	$3.75 - $20.05 $63,071 - $337,220	16,819 New	16,819 $317,000
Q4 2021 Feb 11, 2022	SELL	$4.75 - $7.5 $1.33 Million - $2.1 Million	-279,963 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$5.02 - $6.59 $1.41 Million - $1.84 Million	279,963 New	279,963 $1.59 Million
Q1 2020 May 05, 2020	SELL	$2.12 - $6.8 $61,026 - $195,744	-28,786 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$2.25 - $5.8 $35,239 - $90,839	15,662 Added 119.34%	28,786 $147,000
Q3 2019 Nov 01, 2019	SELL	$2.22 - $3.39 $2,604 - $3,976	-1,173 Reduced 8.2%	13,124 $32,000
Q2 2019 Jul 26, 2019	SELL	$1.8 - $3.3 $100,686 - $184,592	-55,937 Reduced 79.64%	14,297 $31,000
Q1 2019 Apr 24, 2019	BUY	$2.41 - $5.91 $81,303 - $199,379	33,736 Added 92.43%	70,234 $190,000
Q4 2018 Feb 01, 2019	BUY	$3.94 - $9.7 $48,454 - $119,290	12,298 Added 50.82%	36,498 $175,000
Q3 2018 Oct 25, 2018	BUY	$8.6 - $11.26 $163 - $213	19 Added 0.08%	24,200 $229,000
Q2 2018 Jul 20, 2018	BUY	$9.52 - $12.15 $110,327 - $140,806	11,589 Added 92.03%	24,181 $235,000
Q1 2018 Apr 18, 2018	SELL	$6.7 - $12.95 $34,558 - $66,796	-5,158 Reduced 29.06%	12,592 $132,000
Q4 2017 Jan 17, 2018	SELL	$5.07 - $7.92 $91,260 - $142,560	-18,000 Reduced 50.35%	17,750 $114,000
Q3 2017 Oct 17, 2017	BUY	$5.4 - $8.47 $193,050 - $302,802	35,750	35,750 $273,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.